Table 3.

Age-adjusted hazard ratios for all-cause mortality in female breast cancer patients registered in the Biobank Japan Project within 90 days after diagnosis grouped according to characteristics, after a mean follow-up period of 7.8 years.

	Those registered within 90 days after diagnosis
	Participants	Cases	PYFU	Age-adjusted HR (95% CI)
Age at study entry
Additional 1 yr increase				1.04	(1.03–1.05)
Body mass index
<18.5 kg/m2	174	17	1323	1.03	(0.56–1.88)
18.5–24.9 kg/m2	1271	141	9932	1.00	Reference
≥25.0 kg/m2	386	48	3006	0.79	(0.53–1.18)
Additional 1 kg/m2 increase	0.98				(0.94–1.02)
Smoking habit
Never	1416	172	10981	1.00	Reference
Ever (current/former)	439	46	3425	0.97	(0.64–1.46)
Alcohol drinking habit
Never	1075	130	8248	1.00	Reference
Ever (current/former)	777	85	6146	1.06	(0.75–1.52)
Stage
0 or unclassified	138	3	1051	0.65	(0.08–5.28)
I	582	38	4622	1.00	Reference
II	444	50	3528	1.28	(0.64–2.56)
III	33	8	237	16.06	(3.13–82.49)
IV	10	6	39	45.83	(10.83–193.89)
Invasive status
Non-invasive	226	10	1785	1.00	Reference
Invasive	1414	182	11036	2.09	(0.91–4.77)
Serum CEA level
<5 ng/mL	1726	173	13527	1.00	Reference
≥5 ng/mL	90	35	570	3.92	(2.56–6.00)
Serum CA15-3 level
<27 U/mL	1753	181	13753	1.00	Reference
≥27 U/mL	51	27	243	5.16	(3.28–8.13)
Estrogen receptor status
Positive	1149	104	9110	1.00	Reference
Negative	369	55	2795	1.55	(1.01–2.39)
Progesterone receptor status
Positive	934	80	7399	1.00	Reference
Negative	576	77	4437	1.31	(0.86–1.98)

Abbreviations: CA15-3, carbohydrate antigen 15-3; CEA, carcinoembryonic antigen; CI, confidence interval; HR, hazard ratio; PYFU, person-years of follow-up. The hazard ratios were calculated using a Cox proportional hazards regression model stratified by institution and adjusted for age at study entry and entry year.